Integrated Model

We believe that retaining in-house control of the critical stages of developing our drug products, such as GMP manufacture and clinical operations, has allowed us to move quickly and efficiently since starting up in 2014, to being an established immunotherapy company with multiple therapeutic products in our development pipeline today.

In January 2015, TCB’s manufacturing facility at corporate headquarters was awarded a Manufacturer's Authorisation for Investigational Medicinal Products (MIA(IMP)) which permits GMP manufacture and release of Advanced Therapy Medicinal Products (ATMPs) for use in clinical trials. Further to obtaining an MHRA manufacturing license, TCB was granted a Clinical Trial Authorisation (CTA) by the MHRA in September 2015 to commence clinical evaluation of autologous cell therapies built on gamma delta T cell therapies. In the following years expansion of our facility has continued including authorisation for the manufacture of allogeneic GDT cell products. Current capacity allows TCB to fully meet the needs of our clinical development pipeline, with trials being managed by our experienced TCB clinical team.